La maîtrise des plaquettes, un vrai défi?

Platelet aggregation involves different receptors located at the platelet surface, many of which are now well known, with effective inhibitors. Given the risk of thrombosis in acute coronary syndrome, their efficacy remains insufficient, with interpatient variability that exposes nonresponding patients to excessive risk of potentially serious clinical events. Resistance to clopidogrel is related to true genetic determinism for pharmacological reasons. This deficit has made it necessary to develop new drugs such as prasugrel, the new P2Y12 ADP receptor inhibitor. Their aggregation inhibitor action is not only faster-acting, but also more powerful.